Shown verbatim: the complete text as captured from the official PDF posted by the Oklahoma Legislature, fetched 2026-07-23. Page and line markers are part of the official record; nothing is edited or removed. The official bill page.
1 STATE OF OKLAHOMA
1
2 2nd Session of the 60th Legislature (2026)
2
3 SENATE BILL 1306 By: Hicks
3
4
4
5
5
6 AS INTRODUCED
6
7 An Act relating to prescription drugs; defining
7 terms; prohibiting an insurer from modifying coverage
8 under certain conditions; providing certain
8 exceptions; providing for certain civil penalty;
9 requiring promulgation of rules; providing for
9 codification; and providing an effective date.
10
10
11
11
12 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
12
13 SECTION 1. NEW LAW A new section of law to be codified
13
14 in the Oklahoma Statutes as Section 6850.2 of Title 36, unless there
14
15 is created a duplication in numbering, reads as follows:
15
16 A. As used in this section:
16
17 1. "Insurer" means an insurer as defined pursuant to Section
17
18 6054 of Title 36 of the Oklahoma Statutes;
18
19 2. "Practitioner" means a practitioner as defined pursuant to
19
20 Section 6054 of Title 36 of the Oklahoma Statutes; and
20
21 3. "Prescription drug" or "drug" means a prescription drug as
21
22 defined pursuant to Section 367.2 of Title 59 of the Oklahoma
22
23 Statutes.
23
24
24
Req. No. 2648 Page 1
1 B. An insurer shall not modify an insured's coverage of a
1
2 prescription drug if the following conditions are met:
2
3 1. The drug has been previously preauthorized for coverage by
3
4 the insurer or was listed on the formulary of the insurer at the
4
5 time the insured was prescribed the drug by his or her practitioner;
5
6 2. The insured has already received the drug; and
6
7 3. A practitioner continued to prescribe the drug to the
7
8 insured.
8
9 C. Modification prohibited under this section shall include,
9
10 but not be limited to:
10
11 1. Increasing the premium, co-payment, coinsurance, or
11
12 deductible;
12
13 2. Denying or otherwise failing to provide continued coverage
13
14 of the prescription drug;
14
15 3. Moving the drug to a more restrictive coverage category or
15
16 tier; or
16
17 4. Replacing the brand-name drug for a generic drug after the
17
18 insured has qualified for the brand-name drug pursuant to this
18
19 section.
19
20 D. Nothing in this section shall be construed to prohibit an
20
21 insurer from modifying coverage of a prescription drug if:
21
22 1. The United States Food and Drug Administration has issued a
22
23 statement calling into question the clinical safety of the drug; or
23
24
24
Req. No. 2648 Page 2
1 2. The manufacturer of the drug has notified the United States
1
2 Food and Drug Administration of a manufacturing discontinuance or
2
3 potential discontinuance of the drug, as required by 21 U.S.C.,
3
4 Section 356c.
4
5 E. Any insurer that violates the provisions of this section
5
6 shall be subject to a civil penalty in an amount to be determined by
6
7 the Insurance Commissioner. The Insurance Commissioner shall
7
8 promulgate rules to effectuate the provisions of this section.
8
9 SECTION 2. This act shall become effective November 1, 2026.
9
10
10
11 60-2-2648 CAD 12/29/2025 9:10:33 AM
11
12
12
13
13
14
14
15
15
16
16
17
17
18
18
19
19
20
20
21
21
22
22
23
23
24
24
Req. No. 2648 Page 3Every fact on this page links to its source, starting with the official bill record.